Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8+ T Cells.

Zahm CD, Colluru VT, McIlwain SJ, Ong IM, McNeel DG.

Cancer Immunol Res. 2018 Nov;6(11):1364-1374. doi: 10.1158/2326-6066.CIR-18-0243. Epub 2018 Sep 10.

PMID:
30201735
2.

Vaccination with High-Affinity Epitopes Impairs Antitumor Efficacy by Increasing PD-1 Expression on CD8+ T Cells.

Zahm CD, Colluru VT, McNeel DG.

Cancer Immunol Res. 2017 Aug;5(8):630-641. doi: 10.1158/2326-6066.CIR-16-0374. Epub 2017 Jun 20.

3.

DNA vaccines for prostate cancer.

Zahm CD, Colluru VT, McNeel DG.

Pharmacol Ther. 2017 Jun;174:27-42. doi: 10.1016/j.pharmthera.2017.02.016. Epub 2017 Feb 7. Review.

4.

Safety and Immunological Efficacy of a DNA Vaccine Encoding the Androgen Receptor Ligand-Binding Domain (AR-LBD).

Olson BM, Bradley ES, Sawicki T, Zhong W, Ranheim EA, Bloom JE, Colluru VT, Johnson LE, Rekoske BT, Eickhoff JC, McNeel DG.

Prostate. 2017 May;77(7):812-821. doi: 10.1002/pros.23321. Epub 2017 Feb 9.

5.

Mini-intronic plasmid vaccination elicits tolerant LAG3+ CD8+ T cells and inferior antitumor responses.

Colluru VT, Zahm CD, McNeel DG.

Oncoimmunology. 2016 Sep 2;5(10):e1223002. eCollection 2016.

6.

B lymphocytes as direct antigen-presenting cells for anti-tumor DNA vaccines.

Colluru VT, McNeel DG.

Oncotarget. 2016 Oct 18;7(42):67901-67918. doi: 10.18632/oncotarget.12178.

7.

Preclinical and clinical development of DNA vaccines for prostate cancer.

Colluru VT, Johnson LE, Olson BM, McNeel DG.

Urol Oncol. 2016 Apr;34(4):193-204. doi: 10.1016/j.urolonc.2013.09.014. Epub 2013 Dec 12. Review.

8.

In-silico characterization of ECE-1 inhibitors.

Ajay Babu P, Colluru VT, Anaparthy N.

Comput Biol Med. 2012 Apr;42(4):446-57. doi: 10.1016/j.compbiomed.2011.12.013. Epub 2012 Jan 14.

PMID:
22245098

Supplemental Content

Loading ...
Support Center